Syros Pharmaceuticals (NASDAQ:SYRS) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their buy rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) in a report issued on Wednesday, Benzinga reports. The firm currently has a $15.00 price target on the stock. HC Wainwright also issued estimates for Syros Pharmaceuticals’ Q2 2024 earnings at ($0.73) EPS, Q3 2024 earnings at ($0.74) EPS, Q4 […]

Related Keywords

Piper Sandler ,Kennedy Capital Management ,Syros Pharmaceuticals ,News Ratings For Syros Pharmaceuticals Daily ,Syros Pharmaceuticals Stock Performance ,Acadian Asset Management ,Institutional Trading Of Syros Pharmaceuticals ,Opaleye Management Inc ,Syros Pharmaceuticals Inc ,Vanguard Group Inc ,Free Report ,Get Free Report ,Asset Management ,Capital Management ,Vanguard Group ,Syros Pharmaceuticals Daily ,